ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Mar 10, 2023
Dividend Increases/Decreases for the Week of March 10
Let's take a look at firms raising/lowering their dividends this week.
Mar 9, 2023
SVB Financial, Silvergate Capital, Credit Suisse Reveal Cracks in Global Financial System
Image: SVB Financial looks to be collateral damage of the Fed’s rate-hiking cycle, and we can’t rule out that other regional banks could have also managed interest-rate risk wrong. Shares of SVB Financial have collapsed, and other banks could be facing similar issues that have yet to come to light. Image Source: TradingView. SVB Financial announced March 8 what looks to be an emergency equity offering to the tune of $2.25 billion in common stock and convertible preferred shares. The company also announced that it had sold almost all of its available-for-sale (AFS) $21 billion securities portfolio, which resulted in an after-tax loss of ~$1.8 billion during the current quarter. This looks to be an effort to shore up liquidity while it can, and we would not be surprised to see some bad bets at the bank come to light. SVB Financial’s client cash burn has accelerated, and the executive team noted that the “challenging market and rate environment has pressured Q1 performance, with implications to (its) 2023 outlook.” It’s difficult to know just how bad things are at SVB Financial, but the bank seems to have mismanaged interest rate risks and its asset sensitivity. SVB is reconstructing its AFS portfolio with short-duration fixed rate U.S. Treasuries. Though this may be the right move, the stark scenario for the bank is that if market participants lack confidence in the institution, there is more downside to come.
Mar 9, 2023
We Woke Up on the Wrong Side of the Bed
Image: Valuentum's President of Investment Research Brian Nelson, CFA. Let's cover five controversial topics today: 1) Large cap growth still dominating small cap value. 2) Who cares about whether fund managers beat their benchmarks. Pick the best group of stocks, right? 3) Dividends are capital appreciation that otherwise would have been achieved had the dividend not been paid. 4) Go figure -- bonds are down again so far in 2023. 5) REITs are underperformers and haven't been reliable dividend payers.
Mar 6, 2023
Markets Bounce Off Technical Support But Not Out of the Woods
Image: The market-cap weighted S&P 500 (SPY) bounced off technical support last week, both the 200-day moving average as well as the breakout of the downtrend line, but while this may push off any leg down in the near term, we won’t hesitate to “raise cash” on a few newsletter portfolio names if a breakthrough of support to the downside happens. Image Source: TradingView. The 200-day moving average remains a key technical level for the market-cap weighted S&P 500. The risks that the market may break through both the 200-day moving average and the breakout of the technical downtrend line remain elevated, but the past week showed a successful test of technical support levels, in our view, and that means to us markets may avoid any substantial leg down for the time being. We continue to be cautious on the equity markets in the near term, and we won’t hesitate to “raise cash” across the newsletter portfolios if the S&P 500 breaks through its 200-day moving average and the breakout of the technical downtrend line.
Mar 3, 2023
Update: J&J Reports Messy Q4, Free Cash Flow Remains Robust But Looming Kenvue Split Adds Uncertainty
Image: Johnson & Johnson’s free cash flow generation remains far in excess of its cash dividends paid. Image Source: J&J. Johnson & Johnson reported messy fourth-quarter 2022 results that showed a large difference between GAAP and non-GAAP reporting. The company’s free cash flow presentation wasn’t great either, and we can’t help but feel management is a bit distracted given that the firm is working to spin off its Consumer Health division (Kenvue) later during 2023. J&J will retain its two larger divisions, Pharma and MedTech, including its key drugs Stelara, Darzalek, Tremfya, Erleada, and Uptravi, as well as its MedTech operations that have exposure to a number of areas including electrophysiology, wound closure, procedures for knees and hips, as well as surgical vision and trauma. We continue to like J&J’s coverage of the dividend with free cash flow, but we doubt the company will stay in the newsletter portfolios for much longer in light of the messy presentation and impending Kenvue split, expected in November 2023. We like to keep things simple. Shares yield ~2.7%. [We have updated this work to reflect that we are considering removing JNJ from both the Dividend Growth Newsletter portfolio and the Best Ideas Newsletter portfolio.]
Feb 27, 2023
Our Reports on Stocks in the Oil and Gas Complex Industry
Our reports on stocks in the Oil and Gas Complex industry can be found in this article. Reports include BKR, HAL, SLB, BP, CVX, COP, XOM, SHEL, TTE, CTRA, EOG, OXY, PXD, ENB, ET, EPD, MMP, KMI, PSX.
Feb 24, 2023
Dividend Increases/Decreases for the Week of February 24
Let's take a look at firms raising/lowering their dividends this week.
Feb 23, 2023
This Remains a Technically-Driven Stock Market
Image: We expect the S&P 500 (SPY) to test support at both its technical uptrend and the 200-day moving average. In the event the SPY breaks through technical support, we’d be looking to “raise cash” across the newsletter portfolios. S&P 500 companies will end 2022 with roughly a 4%-5% decline in fourth-quarter 2022 earnings, but earnings season has come in better-than-feared. We expect the Fed to continue to raise rates given recent producer price inflation readings and a continued strong labor market. The 10-year Treasury continues to pose headwinds to asset values, and while many are talking of “disinflation,” we expect the market to remain technically driven and begin to test support at the 200-day moving average across major indices. We believe 2023 will be a choppy year, as we look ahead to better times in 2024.
Feb 22, 2023
Follow Up on Intel’s Dividend Cut: We Will Strive to Do a Better Job Communicating
As noted in our brief note on Intel this morning, “Intel Cuts Dividend, As Expected,” we have now refreshed the company’s reports on the website, with updated Dividend Safety and Dividend Growth Potential ratings, both as VERY POOR. After factoring in Intel’s updated outlook to our valuation model from its fourth-quarter release, our updated fair value estimate is now $25 per share (was $27 per share) and our updated Dividend Cushion ratio is -1.7 (negative 1.7), was 0.4. This includes the dividend cut.
Feb 22, 2023
Intel Cuts Dividend, As Expected
Image Source: Aaron Fulkerson. The Dividend Cushion ratio caught another dividend cut. This time it was Intel’s. With a Dividend Cushion ratio of 0.4, Intel announced February 22 that it has slashed its dividend by nearly two thirds, to $0.125 on a quarterly basis, down from its prior quarterly dividend of $0.365. The company’s estimated forward yield now stands at ~1.9%, and we can’t say that the dividend cut was unexpected given its massive net debt position and significantly weakened free cash flow generation--the two most important components behind an assessment of its cash-based intrinsic value and dividend health.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.